Unknown

Dataset Information

0

Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date.


ABSTRACT: Myelofibrosis is a heterogeneous disorder with regard to both molecular pathogenesis and clinical phenotype, ranging from an initial fairly indolent condition in some through to an aggressive and debilitating scenario with profound constitutional symptoms, cytopenia frequently requiring transfusional support, and massive splenomegaly. Many advances have been made within the therapeutic arena, and an increasing array of novel agents are now available for disease management. Within this review, we focus on the current and predicted role of the JAK inhibitor momelotinib (Sierra Oncology) in myelofibrosis, with an emphasis on clinical trial evaluation, drug efficacyand safety, and discuss the suggested place in the therapeutic paradigm of myelofibrosis in 2020 and beyond.

SUBMITTER: Bassiony S 

PROVIDER: S-EPMC7524184 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date.

Bassiony Sarah S   Harrison Claire N CN   McLornan Donal P DP  

Therapeutics and clinical risk management 20200925


Myelofibrosis is a heterogeneous disorder with regard to both molecular pathogenesis and clinical phenotype, ranging from an initial fairly indolent condition in some through to an aggressive and debilitating scenario with profound constitutional symptoms, cytopenia frequently requiring transfusional support, and massive splenomegaly. Many advances have been made within the therapeutic arena, and an increasing array of novel agents are now available for disease management. Within this review, we  ...[more]

Similar Datasets

| S-EPMC6886547 | biostudies-literature
| S-EPMC5210237 | biostudies-literature
| S-EPMC7351990 | biostudies-literature
2013-01-14 | E-GEOD-40841 | biostudies-arrayexpress
| S-EPMC5841331 | biostudies-literature
| S-EPMC8772195 | biostudies-literature
2013-01-14 | GSE40841 | GEO
| S-EPMC6259025 | biostudies-literature
| S-EPMC6788387 | biostudies-literature
| S-EPMC7245454 | biostudies-literature